Dombeck M, Earnshaw SR, Candrilli SD, Xuan J, Bakst A, Kirsch JM. Modeling antibiotic efficacy by infectious agent and probability of resistance. Poster presented at the International Society for Pharmacoeconomics and Outcomes Research 4th Annual European Congress; November 2001. [abstract] Value Health. 2001 Sep; 4(6):427.


Current cost-effectiveness models of antibiotic efficacy typically do not consider the variability in relative incidence of infectious agents or the probability of species-specific antibiotic resistance. A model that incorporates this variability in incidence and resistance will more accurately represent epidemiological variances and associated differences in treatment costs across patient populations.

OBJECTIVES: To create a model of antibiotic efficacy that generates population-specific cost-effectiveness ratios by including incidence and resistance rates of infectious agents and can be adjusted to reflect epidemiological data specific to different geographic regions.

METHODS: We constructed a decision tree model that represents a user-defined infection (i.e. acute exacerbation of chronic bronchitis). This model considers the relative incidence of infectious agents (bacterial and nonbacterial/ viral), the incidence of resistance among the bacteria agents, and antibiotic efficacy against each infectious agent and level of resistance. The model can represent “all-or-none” resistance such as that associated with beta-lactamase production, or varying degrees of susceptibility associated with other methods of resistance. The model can represent clinical or in vitro efficacy, depending on the source of the data. In the event of insufficient data to populate the resistance branch, this branch can be collapsed out of the tree. The model will then represent antibiotic efficacy for all infectious agents included.

RESULTS:
The model generates cost-effectiveness ratios identifying conditions where the antibiotic of interest is cost effective or cost saving versus other antibiotics. Ratios for individual infectious agents and levels of resistance also identify specific populations where the antibiotic of interest has an advantage.

CONCLUSIONS: This model can incorporate geographic diversity of and resistance in bacterial populations to generate cost-effectiveness ratios specific to different epidemiological and geographic populations.

Share on: